

October 10, 2017

Change to Vaccine Products – Quadracel® & Infanrix®-IPV no longer available

Quadracel® and Infanrix®-IPV (DTaP-IPV) vaccines are no longer available in Canada. These vaccines were provided to a small group of children less than seven years of age who were completing a catch-up primary series.

Replacement product:

Effective immediately, Pediacel® vaccine (DTaP-IPV-Hib) will permanently replace Quadracel® and Infanrix®-IPV vaccine. After consultation with Public Health Ontario, the Ministry of Health and Long-term Care has determined Pediacel® is an appropriate substitute, despite the extra dose of Haemophilus influenzae B (Hib). Extra doses of Hib to older children are safe.

Vaccine orders:

Health care providers that currently have DTaP-IPV vaccine orders at OGPMS, your orders will be cancelled; use your existing Pediacel® vaccine stock and/or place a new order.

Summary of Pediacel® vaccine:

- Contains added Hib protection compared to Quadracel/Infanrix-IPV
- Is licensed for children, 2 months of age to less than seven years of age
- The risk of Hib infection is predominant in infants and children up to age 4 years.
- For healthy children 5 years of age and older, the Hib component of the vaccine is not routinely indicated according to the National Advisory Committee on Immunization; however providing additional doses to older children in this multi-antigen vaccine is not harmful.
- Some older children and adults with certain chronic conditions with increased risk of invasive Hib disease are immunized regularly with the Hib vaccine

Have questions? Call Toronto Public Health Immunization Nursing Line at 416-338-2030.